EMA maintains marketing authorization for Fulphila, Biocon, ensuring continued competition in the supportive cancer care market.
Regulatory Status and History
Fulphila (pegfilgrastim) is a biosimilar designed to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients with cancer undergoing cytotoxic chemotherapy. The European Commission granted marketing authorization valid throughout the European Union on November 20, 2018, and it is currently in the marketed phase. Prior to this, the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) issued a positive opinion on September 19, 2018. Therefore, this EMA document should be interpreted as a regulatory record demonstrating the maintenance of existing authorization and product information, rather than a new approval event.
Mechanism of Action and Clinical Evidence
Pegfilgrastim is a long-acting hematopoietic growth factor that stimulates granulocyte colony-stimulating factor (G-CSF) receptors, thereby promoting the production and differentiation of myeloid progenitor cells in the bone marrow. It is conjugated with polyethylene glycol, resulting in slower elimination from the body compared to filgrastim, and is administered at a dose of 6 mg per chemotherapy cycle. The EMA determined that Fulphila is highly similar to Neulasta (pegfilgrastim) from Amgen (AMGN) in terms of structure, purity, biological activity, and in vivo distribution. The assessment of clinical equivalence did not demonstrate new superiority but established comparable quality, safety, and efficacy compared to the reference product, which is significant in terms of reducing development costs and market entry barriers.
Development Path and Ownership Structure
Mylan withdrew its previous European marketing application on August 3, 2017, because it failed to secure the Good Manufacturing Practice (GMP) certificate for its manufacturing facility within the review period. However, after addressing the deficiencies, it resubmitted the application and obtained approval in 2018. The U.S. Food and Drug Administration (FDA) approved Fulphila as the first Neulasta biosimilar in the U.S. on June 4, 2018, and the U.S. labeling indicates pegfilgrastim-jmdb. Currently, the European marketing authorization holder is Biosimilar Collaborations Ireland, and Biocon Biologics took over the European commercial and regulatory operations from Viatris (VTRS) after acquiring Viatris' global biosimilar business in November 2022. This structure demonstrates that the value of Fulphila lies in Biocon's integrated production and distribution capabilities and portfolio scale, rather than as a single product.
Market and Competitive Landscape
The 2025 global sales of the reference drug, Neulasta, were $435 million, comprising $359 million in the U.S. and $76 million in other regions, indicating a mature but still significant prescription base. In Europe, Fulphila competes with other pegfilgrastim biosimilars, such as Ziextenzo from Sandoz, Nyvepria, Pelmeg, and Stimufend from Pfizer (PFE), for the same indications. The standard prophylactic options also include short-acting G-CSF, such as Neupogen (filgrastim) and its biosimilars. Price, bidding, and supply stability are key factors influencing market share. The maintenance of Fulphila's EMA approval provides Biocon with a basis for participating in European oncology supportive care tenders, but with numerous equivalent products available, manufacturing costs and commercial execution are more critical than growth potential.
Fulphila is a G-CSF biosimilar in the marketed phase in Europe, having received approval in November 2018, and its short-term performance is determined more by maintaining approval and ensuring supply than by new clinical catalysts. The $435 million in global sales of the reference drug, Neulasta, in 2025 demonstrates the market's cash-generating potential, but competition from Ziextenzo, Nyvepria, Pelmeg, and Stimufend puts pressure on prices and margins. From a research perspective, the comparative equivalence pathway of pegfilgrastim, which targets G-CSF receptors, is a case study demonstrating the efficiency of biosimilar development. Biocon Biologics strengthened its direct sales base in Europe by acquiring Viatris' biosimilar business for up to $3.335 billion in 2022, and its medium- to long-term value depends on production costs, tender wins, and cross-selling performance within its portfolio.
Source: EMA (ema)